Your session is about to expire
← Back to Search
Tirabrutinib for Central Nervous System Lymphoma
Study Summary
This trial will study the effects of a new drug, tirabrutinib, on patients with relapsed or refractory PCNSL (part A), and on patients with newly diagnosed, treatment naïve PCNSL (part B).
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2019 Phase 2 trial • 152 Patients • NCT03100942Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You are expected to live for at least 6 more months.I can take care of myself and perform daily activities.I am 18 years old or older.You need to sign a paper saying you agree to participate before you can be checked for eligibility.I cannot swallow pills or have a condition affecting my stomach or intestines.I do not have an active infection or have not been hospitalized for an infection requiring IV antibiotics in the last 28 days.You have had an allergic reaction to the dye used in MRI scans.My kidney, liver, and bone marrow are functioning well.I have a brain lesion larger than 1 cm, confirmed by a recent MRI.I have had an organ transplant.I have not received any treatment for my brain lymphoma.I haven't taken systemic steroids regularly in the last 14 days, except for specific exceptions.I have been treated with a BTK inhibitor before.I have a brain lesion larger than 1 cm, confirmed by a recent MRI.You are expected to live for at least 3 more months.You have had a serious skin reaction called Stevens Johnson Syndrome or Toxic Epidermal Necrolysis in the past.I am unable to give consent due to a condition like dementia.My lymphoma has spread throughout my body.I am not pregnant or breastfeeding.I haven't taken any experimental drugs within the last 28 days or 5 half-lives, whichever is shorter.I haven't taken any CYP3A4 or P-gp inducer drugs in the last 14 days.I have another cancer besides PCNSL that needs treatment.My cancer is in the eye and has not spread to the brain.The medications methotrexate, temozolomide, rituximab, procarbazine, and vincristine are not safe for me.My heart's electrical cycle is longer than normal or I'm on medication that affects it.I do not have severe heart, lung, or liver diseases that could affect my treatment.I have tested positive for HIV, HTLV-1, hepatitis B, or hepatitis C.Requirements for being eligible to participate in Part B of the study.I have had moderate to severe liver problems.I have been diagnosed with primary central nervous system lymphoma.My brain lymphoma has returned or didn't respond to treatment with high-dose methotrexate.I was diagnosed with primary central nervous system lymphoma less than 3 months ago.I am taking up to 10 mg/day of prednisone for a condition that is not brain lymphoma.I haven't had certain cancer treatments or major surgery within specific time frames before starting tirabrutinib.I am taking up to 50 mg/day of prednisone for brain or spinal cord lesions.I have a bleeding disorder.My cancer is a non-B cell type of primary central nervous system lymphoma.I haven't taken blood thinners or antiplatelet drugs in the last 7 days.Requirements for being eligible to participate in the study (Part A).You have had severe side effects or allergic reactions to the medications used in the study before.My doctor thinks I can handle a high dose methotrexate treatment.
- Group 1: Tirabrutinib monotherapy in patients with relapsed or refractory PCNSL (Part A)
- Group 2: Tirabrutinib + MTR in patients with newly diagnosed, treatment naïve PCNSL (Part B, Arm 1)
- Group 3: Tirabrutinib + R-MPV in patients with newly diagnosed, treatment naïve PCNSL (Part B, Arm 2)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Have any other research projects been conducted with Tirabrutinib?
"Tirabrutinib was first trialed at the Plymouth Hospitals NHS Trust back in 2015 and 6 completed studies have since been conducted. Currently, two clinical trials are underway with one based out of Louisville, Kentucky."
Is the enrollment phase of this clinical trial still open?
"As per the information held on clinicaltrials.gov, this trial is actively looking for participants. The study was made available online on December 29th 2021 and its details were last updated on June 15 2022."
What potential perils does taking Tirabrutinib carry for those who ingest it?
"Tirabrutinib was assigned a score of 2 on the safety scale, as there is evidence that it can be tolerated but no proof yet to support its efficacy."
Are there any facilities in North America offering this clinical experiment?
"Patients for this trial are being accepted at Norton Cancer Institute - St. Matthews in Louisville, Kentucky, The University of Kansas Cancer Center (KUCC) (Kansas City Cancer Center (KCCC)) - North in Kansas City, Missouri, Henry Ford Hospital in Detroit, Michigan and an additional 34 sites."
Is this experiment a pioneering endeavor?
"Currently, two clinical trials are active for Tirabrutinib across 30 cities in three nations. This drug was first tested by Gilead Sciences in 2015 with a cohort of 202 patients and achieved Phase 1 approval status. Since then, six additional studies have been finalized."
How many participants can this trial accommodate?
"This medical trial needs 112 patients that adhere to the requisite eligibility criteria. Potential research participants can join this study at Norton Cancer Institute - St. Matthews in Louisville, Kentucky and The University of Kansas Cancer Center (KUCC) (Kansas City Cancer Center (KCCC)) - North in Kansas City, Missouri."
Share this study with friends
Copy Link
Messenger